Convertible Promissory Notes and Notes Payable (Details Narrative) - USD ($) |
1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 07, 2025 |
Jul. 08, 2024 |
Feb. 10, 2025 |
Feb. 22, 2023 |
Oct. 19, 2022 |
Jun. 30, 2022 |
Mar. 31, 2025 |
Mar. 31, 2025 |
Jun. 30, 2024 |
Jun. 30, 2023 |
Dec. 31, 2022 |
Dec. 31, 2024 |
Jan. 18, 2024 |
Apr. 15, 2022 |
|
| Additional warrants shares issued | 116,668 | |||||||||||||
| Market price of issuance shares | $ 2.74 | |||||||||||||
| Unamortized debt discount | $ 213,813 | |||||||||||||
| Expected volatility | 253.00% | |||||||||||||
| Risk-free interest rate | 3.99% | |||||||||||||
| Expected term | 2 years | |||||||||||||
| Intrinsic values of debt discount | $ 107,262 | $ 115,865 | ||||||||||||
| Common stock per share | $ 19.94 | |||||||||||||
| Proceeds from related party | $ 100,000 | $ 0 | ||||||||||||
| Interest rate | 8.50% | |||||||||||||
| Investor [Member] | ||||||||||||||
| Original principal amount | $ 350,000 | |||||||||||||
| Description of amendment to the promissory note | The term of the note is two (2) years and has an interest rate of three (3) percent. There are no interest or principal payments due during the term of the note. All principal and interest not converted during the term of the note is payable on March 7, 2027 | |||||||||||||
| Common stock per share | $ 3.00 | |||||||||||||
| Promissory note Feb 22, 2023 [Member] | ||||||||||||||
| Description of amendment to the promissory note | the Company executed an amendment to the promissory note with the investor, providing for the payment of interest only for 18 months at 12% per annum and thereafter the amortization of the note over a 12-month period, starting in June of 2025 | |||||||||||||
| Common stock per share | $ 22.00 | |||||||||||||
| Promissory notes Principal amount | $ 560,000 | |||||||||||||
| Principal outstanding amount | $ 560,000 | |||||||||||||
| Common stock share purchase | 6,250 | |||||||||||||
| Promissory note Feb 22, 2023 One [Member] | ||||||||||||||
| Description of amendment to the promissory note | the Company executed an amendment to the promissory note with the investor, providing for the payment of interest only for 18 months at 12% per annum and thereafter the amortization of the note over a 12-month period, starting in June of 2025 | |||||||||||||
| Common stock per share | $ 22.00 | |||||||||||||
| Promissory notes Principal amount | $ 2,150,000 | |||||||||||||
| Principal outstanding amount | $ 2,150,000 | |||||||||||||
| Common stock share purchase | 25,000 | |||||||||||||
| Promissory note Feb 22, 2023 Two [Member] | ||||||||||||||
| Common stock per share | $ 2.28 | |||||||||||||
| Promissory notes Principal amount | $ 650,000 | |||||||||||||
| Converted shares | 285,000 | |||||||||||||
| Note Agreement [Member] | ||||||||||||||
| Holdback amount | $ 500,000 | |||||||||||||
| Convertible Notes, 36-Month Term Notes [Member] | ||||||||||||||
| Proceeds from related party | 7,500,000 | |||||||||||||
| Sales of building | $ 4,300,000 | |||||||||||||
| Fund received from accredited investors | 15,000,000 | |||||||||||||
| Proceeds from notes | $ 2,780,200 | 6,678,506 | ||||||||||||
| Description of agreement | The Company received a forbearance agreement from the bank until June 30, 2024 to return to compliance of the debt service ratio of 1.25 to 1, until that time the Company will pay an interest rate of 10% instead of the contractual terms of 4.8% | |||||||||||||
| Holdback amount | $ 3,000,000 | |||||||||||||
| Warrants acquire | $ 2,813 | |||||||||||||
| Exercise price | $ 88.80 | |||||||||||||
| Gain in the change of derivative liability | $ 3,540 | |||||||||||||
| Redeem warrants | $ 250,000 | |||||||||||||
| Allan Marshall [Member] | ||||||||||||||
| Description of amendment to the promissory note | the Company executed an amendment to the promissory note with Mr. Marshall, providing for the payment of interest only for 18 months at an interest rate of 12% per annum and thereafter the amortization of the note over a 12 month period, starting in June of 2025 | |||||||||||||
| Common stock per share | $ 22.00 | |||||||||||||
| Promissory notes Principal amount | $ 1,500,000 | |||||||||||||
| Principal outstanding amount | $ 500,000 | |||||||||||||
| Common stock share purchase | 18,750 | |||||||||||||
| Interest rate | 8.50% | |||||||||||||
| Interest rate pik | 3.50% | |||||||||||||
| Cygnet Note [Member] | ||||||||||||||
| Common stock per share | $ 120.00 | |||||||||||||
| Promissory notes Principal amount | $ 1,050,000 | |||||||||||||
| VitaMedica Note [Member] | ||||||||||||||
| Promissory notes Principal amount | $ 500,000 | |||||||||||||
| Total convertible common stock | $ 100,000 | $ 1,000,000 | ||||||||||||